Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Alabama at Birmingham |
---|---|
Information provided by: | University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT00584883 |
To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Condition | Intervention | Phase |
---|---|---|
Brain Tumor |
Drug: ABT 510 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1 Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastma Multiforme |
Enrollment: | 24 |
Study Start Date: | August 2003 |
Study Completion Date: | October 2007 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients who have received any other investigational agents within the 28 days prior to Day 1 of the study.
-
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294 |
Principal Investigator: | Louis B Nabors, MD | University of Alabama at Birmingham |
Responsible Party: | University of Alabama at Birmingham ( Louis Burton Nabors, MD ) |
Study ID Numbers: | F030804016, ABT510 |
Study First Received: | December 26, 2007 |
Last Updated: | December 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00584883 |
Health Authority: | United States: Food and Drug Administration |
Patients who have newly diagnosed brain tumors |
Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms |
Brain Diseases Temozolomide Nervous System Neoplasms |
Neoplasms Neoplasms by Site Nervous System Diseases |